Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sale of clinical immuno chemiluminescence diagnostic reagents and instruments in China. The company offers the LiCA series of diagnostic reagents, which is based on photo-induced chemiluminescence; the Chemclin series of diagnostic reagents and instruments, which is based on enzyme-catalyzed chemiluminescence; and routine clinical chemistry diagnostic reagents. Its products are used for the detection of biomarkers for infectious diseases, such as hepatitis B, hepatitis C, HIV, syphilis, hepatitis A, and hepatitis E, etc., as well as of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company serves large and medium-sized hospitals, health check-up centers, emergency rooms, clinical laboratories, emergency departments, chest pain centers, and community centers. Chemclin Diagnostics Co., Ltd. was founded in 2005 and is headquartered in Beijing, China.